A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-01-21. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellcancermalignancieslymphomamcl
  Phrases that lowered it: participantsefficacymonotherapyopen labelstudy
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 29.3% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 4 (raises risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Keywords listed: 19 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 12396 (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Design: sequential (raises risk) · Design
• Sponsor's past trials: 4 (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies NCT05107856 · started 2022 · scored riskier than 57% of active trials terminated
• A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies NCT04543305 · started 2020 · scored riskier than 56% of active trials completed
• A Study of PRT1419 in Patients With Advanced Solid Tumors NCT04837677 · started 2021 · scored riskier than 54% of active trials completed
• Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies NCT03263637 · started 2017 · scored riskier than 39% of active trials completed
• Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) NCT02684617 · started 2016 · scored riskier than 61% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.